In a report released today, Francois Brisebois from LifeSci Capital maintained a Buy rating on Opus Genetics, with a price target of $9.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Francois Brisebois has given his Buy rating due to a combination of factors, including Opus Genetics’ strategic focus on inherited retinal diseases where there is substantial unmet medical need and limited competition. He highlights the company’s advancing LCA5 and BEST1 gene therapy programs, with upcoming Phase 1/2 readouts that could serve as important value inflection points if safety and early efficacy trends remain favorable.
He also points to the broader commercial potential of Opus Genetics’ IRD pipeline, supported by specialist KOL engagement such as the post-ARVO call with Dr. Christine Kay, which underscores clinical enthusiasm and a robust patient base for future trials and commercialization. In addition, Brisebois notes that the company’s cash position and projected runway appear sufficient to reach key mid-year data milestones, reinforcing his view that the current valuation does not fully reflect the upside from these forthcoming catalysts.